Response-driven movement control with AUSTEDO1

Dial representing starting dose of 12 mg/day to maximum dose of 48 mg/day. In the FIRST-HD clinical trial, the average daily dose of AUSTEDO® (deutetrabenazine) tablets after titration was >36 mg/day. Dial representing starting dose of 12 mg/day to maximum dose of 48 mg/day. In the FIRST-HD clinical trial, the average daily dose of AUSTEDO® (deutetrabenazine) tablets after titration was >36 mg/day.

AUSTEDO offers multiple therapeutic dosing options.1

Please see additional dosing and administration information at the bottom of this page.

AUSTEDO dosing should increase until symptom control is effectively and tolerably achieved1

Start treatment at 12 mg/day

Blue arrow pointing right Blue arrow pointing right

Increase by 6 mg/day weekly1

Ascending bar graph representing the titration schedule through Week 7 for patients with HD chorea. Ascending bar graph representing the titration schedule through Week 7 for patients with HD chorea.

AUSTEDO is available in 6-mg, 9-mg, and 12-mg tablets1

6 mg AUSTEDO® (deutetrabenazine) tablet. 9 mg AUSTEDO® (deutetrabenazine) tablet. 12 mg AUSTEDO® (deutetrabenazine) tablet.

Tablets not shown at actual size.

Additional dosing and
administration information1

  • Administer total daily dosages above 6 mg/day in 2 divided doses
  • AUSTEDO should be taken with food
  • AUSTEDO should be swallowed whole. Tablets should not be chewed, crushed, or broken
  • Starting dose differs for patients switching from tetrabenazine

REFERENCE: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc.